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Dronedarone: A New Generation of Anti-arrhythmic Drug for the
Treatment of Atrial Fibrillation
NGAI-YIN CHAN,1 SUET-TING LAU,1 CHU-PAK LAU2
From 1Department of Medicine & Geriatrics, Princess Margaret Hospital; 2Hong Kong Sanatorium and Hospital,
Hong Kong
CHAN ET AL.: Dronedarone: A New Generation of Anti-arrhythmic Drug for the Treatment of Atrial Fibrillation.
Amiodarone is currently the most effective anti-arrhythmic drug for the treatment of atrial fibrillation. Its
chronic use, however, has been associated with serious extra-cardiac adverse effects. Dronedarone is a new
anti-arrhythmic drug that does not possess the different organ toxicities associated with amiodarone. With the
addition of a methylsulfonyl group and the removal of iodine moieties, dronedarone has lower tissue accumulation
and a shorter half-life than amiodarone. Dronedarone is a potent blocker of multiple ion currents, including the
rapidly activating delayed-rectifier potassium current, the slowly activating delayed-rectifier potassium current,
the inward rectifier potassium current, the acetylcholine activated potassium current, peak sodium current, and
L-type calcium current, and exhibits antiadrenergic and coronary vasodilatatory effects. Although less effective
than amiodarone as a rhythm-control agent, dronedarone has been shown to reduce ventricular rate and AF
recurrence and it is the first anti-arrhythmic drug shown to reduce the combined outcome of cardiovascular
mortality and hospitalization in AF patients. Dronedarone, however, is contraindicated in patients with moderate
to severe heart failure. The most common side-effects associated with dronedarone are gastrointestinal including
nausea, vomiting and diarrhea. This article will review the current evidence of safety and effectiveness of
dronedarone in treating patients with atrial fibrillation and the position of this new drug in the currently available
anti-arrhythmic armamentarium will be discussed. (J HK Coll Cardiol 2010;18:1-10)
Amiodarone, anti-arrhythmic drug, atrial fibrillation, dronedarone
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Introduction
Atrial fibrillation (AF) is the most common
arrhythmia in clinical practice.1,2 The prevalence of AF
increases with age, from 0.7% in people aged 55-59
years to 18% in those older than 85 years.3 The number
of patients suffering from AF in Hong Kong is expected
to be on an increasing trend as the proportion of elderly
continues to grow.4 Although not immediately lifethreatening, AF does result in significant morbidity,
namely a three-fold increase in the risk of congestive
heart failure, a five-fold increase in the risk of stroke
and a two-fold increase in mortality.5,6
The integral components of treatment for AF
include anticoagulation for stroke prevention and either
one of the strategies, namely rate-control or rhythmcontrol.5 With the currently available anti-arrhythmic
drugs for rhythm-control, no difference in the incidence
of mortality or stroke could be found between the two
strategies.7 On the other hand, the strategy of rhythmcontrol resulted in a higher incidence of hospitalizations
and drug-related adverse events.
Currently available anti-arrhythmic drugs for the
treatment of AF are limited by their suboptimal efficacy
and safety. In the AFFIRM study, only 62.6% of patients
were maintained in sinus rhythm at 5-year follow-up.7
37.5% of patients crossed over from rhythm-control arm
to rate-control arm because of development of persistent
AF or adverse drug effects. Amiodarone is the most
effective anti-arrhythmic drug for AF and is used most
commonly in the AFFIRM study. However, it is
associated with different organ toxicities, e.g. corneal
microdeposits (>90%), hyperthyroidism (0.9-2%),
hypothyroidism (6%), liver function derangement (1530%) and pulmonary toxicity (1-17%), and its long halflife leads to drug accumulation in the body.8
There is significant advancement in both nonpharmacological and pharmacological treatment for AF
in recent years. Catheter ablation, with evolution over
10 years, has been put as a reasonable alternative to
pharmacological therapy to prevent recurrent AF in
symptomatic patients with little or no left atrial
enlargement.5 On the other hand, dronedarone, a new
generation of anti-arrhythmic drug for the treatment of
AF, has been tested in different clinical trials with
promising results. The present review focuses on
2

pharmacological and electrophysiological features of
dronedarone and the results of major clinical studies
with this drug.

Pharmacodynamics and
Electrophysiological Properties of
Dronedarone
Dronedarone is a synthetic benzofuran,
amiodarone derivative that is structurally modified to
reduce toxicities associated with chronic amiodarone
therapy. The addition of methylsulfonyl group makes
dronedarone more water-soluble and less likely to
accumulate in organ tissue while the removal of 2 iodine
atoms prevent the accumulation of the drug in the
thyroid gland and other organs, thus avoiding the organ
toxicities of Amiodarone (Figure 1).9-11
Dronedarone has a complex electrophysiological
profile with multichannel-blocking properties. 10 It
delays the action potential repolarization by blocking
both the rapid and slow component of the delayed
rectifier potassium current. The blockade of both
channels decreases the risk of early after-depolarization
and thus torsades de pointes. Dronedarone has also been
shown to block the slow L-type calcium current and the
sodium current. In addition, dronedarone also inhibits
the muscarinic acetylcholine receptor-operated

Figure 1. Chemical structures of dronedarone and
amiodarone. (Reproduced from Singh BN. Amiodarone as
paradigm for developing new drugs for atrial fibrillation.
J Cardiovasc Pharmacol 2008;52:300-5 with the permission
from Wolters Kluwer Health)11

April 2010

J HK Coll Cardiol, Vol 18

CHAN ET AL.

potassium current. This may contribute partly to the antiarrhythmic effect of dronedarone since vagal activation
may be important in the pathophysiology of AF in some
patients.12,13
Similar to amiodarone, dronedarone has
anti-adrenergic effects by antagonizing α and βadrenoceptors14 and it possesses coronary vasodilating
properties.15 These pharmacological properties may lead
to favourable clinical cardiovascular outcomes.16

Pharmacokinetics of Dronedarone
Dronedarone is well absorbed by oral route (7090%). Absorption increases by 2 to 3-fold when it is
taken with food. Dronedarone undergoes significant
first-pass metabolism with subsequent reduction of
bioavailability to 15%. With drug administration of
400 mg twice daily, steady state plasma concentration
was reached in 7 days. The clearance of dronedarone is
mainly non-renal with a terminal half-life of 24 hours.17
Dronedarone is a substrate for and a moderate
inhibitor of CYP3A4.18 As a result, dronedarone should
not be given with potent CYP3A4 inhibitors like
antifungals, macrolide antibiotics or protease inhibitors
which may increase dronedarone exposure by as much
as 25-fold. When given together with moderate CYP3A4
inhibitors like verapamil and diltiazam, lower doses of
concomitant drugs should be used to avoid severe
bradycardia and conduction block.
Likely a result of P-glycoprotein-mediated
interaction in the kidney, concomitant administration
of dronedarone with digoxin results in a 1.7 to 2.5-fold
increase in serum concentration of digoxin.17 On the
other hand, serum level of simvastatin, a CYP3A4
substrate is increased 2 to 4-fold when given with
dronedarone.
Dronedarone is also a CYP2D6 inhibitor. It
causes a modest increase in bioavailability of metoprolol
in CYP2D6 extensive metabolizers.18 Like amiodarone,
dronedarone leads to partial inhibition of tubular
transport of creatinine. This leads to increase in serum
creatinine concentration which is not related to reduced
glomerular filtration or renal function.19
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Rate-Control With Dronedarone
(ERATO)
In the ERATO (Efficacy and Safety of
Dronedarone for Control of Ventricular Rate) study, 174
elderly patients were randomized to receive 800 mg of
dronedarone daily or placebo. 20 All patients had
suboptimal rate control defined by a resting heart rate
of ≥80 beats per minute despite prior rate-control
therapy with β-blockers, digoxin or calcium channel
blockers. Majority of patients had structural heart
disease but none had severe heart failure.
In the ERATO study, a satisfactory ventricular
rate reduction of 11.7 beats per minute at rest and 24.5
beats per minute during exercise was achieved in
patients taking dronedarone. However, no change in
exercise tolerance was observed in the dronedarone
group. There were no adverse interactions between
dronedarone and other rate-control drugs or
anticoagulants, apart from a 41% increase in serum
digoxin level. While there were no occurrence of organ
toxicity or pro-arrhythmia, the general incidence of side
effects including gastrointestinal problems were
relatively higher in the dronedarone arm compared to
the placebo arm.

Rhythm-Control With Dronedarone
(DAFNE, EURIDIS and ADONIS) (Table 1)
DAFNE (Dronedarone Atrial Fibrillation Study
After Electrical Cardioversion) was a prospective,
randomized and dose-finding study. Two hundred and
seventy patients with persistent AF were randomized
to receive dronedarone 400 mg BD, 600 mg BD,
800 mg BD or placebo.21 There was a dose-dependent
conversion to sinus rhythm in 5.8%, 8.2% and 14.8%
of patients in the 3 dose groups, respectively, compared
to 3.1% in the placebo group. Upon failure of conversion
to sinus rhythm within 5-7 days of dronedarone
treatment, patients were electrically cardioverted. One
hundred ninety-nine patients who were in sinus rhythm
were planned to take dronedarone for 6 months.
The primary endpoint in DAFNE was the time to
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Table 1. Summary of major clinical trials on dronedarone
Trial
DAFNE

Subjects enrolled
N=270
Persistent AF

Follow-up period
6 months

Main outcome
First AF recurrence was
5.8% with 800 mg, 8.2% with
1200 mg and 14.8% with 1600 mg
dronedarone vs 3.1% in placebo
(p=0.0261)

Common side effects
Gastrointestinal

EURIDIS and
ADONIS

N=612 in EURIDIS
N= 625 in ADONIS
Paroxysmal AF

12 months

First recurrence of AF/AFL was
64.1% with dronedarone vs 75.2%
with placebo (p<0.001)

Gastrointestinal
(diarrhea)

ERATO

N=174
Permanent AF

6 months

Reduction of 11.7 beats per
minute in ventricular rate at day
14 (p<0.0001) - this effect was
sustained for the duration of trial
(-8.8 beat/minute at 4 months)
(p<0.001)

Infections
Mild increase in
serum creatinine
levels

13 months (including
additional 6 months
after premature
discontinuation
of study)

Premature termination of trial due
to excess mortality related to the
worsening of heart failure in
dronedarone group
(hazard ratio of 2.13; 85%
CI 1.07 to 4.25; p=0.003)

Worsening heart
failure
Increase in serum
creatinine levels

First hospitalization due to
cardiovascular events or death
was 31.9% in dronedarone
group vs 39.4% in placebo
group (hazard ratio of 0.76;
95% CI 0.69 to 0.84; p<0.001)

Gastrointestinal
(diarrhea, nausea)
Increase in serum
creatinine levels
Rash, bradycardia

ANDROMEDA N=627
NYHA Class III/IV
CHF or PND plus
LVEF<35%

ATHENA

N=4628
21 months
Paroxysmal/persistent
AF/atrial flutter plus
at least one additional
cardiovascular risk factor

AF=atrial fibrillation; NYHA=New York Heart Association; CHF=congestive heart failure; PND=paroxysmal nocturnal dyspnoea; LVEF=left
ventricular ejection fraction.

first recurrence of AF defined as any documented
episode of duration ≥10 minutes, during the 6 months
of follow-up. Dronedarone 400 mg BD was found to
significantly prolong the time to first AF recurrence
compared to placebo (60 days vs 5.3 days, p=0.001).
The ventricular rates during AF recurrence also
decreased significantly and in a dose-dependent manner.
After 6 months, 35% of patients taking dronedarone
400 mg BD and 10% of patients in the placebo group
were in sinus rhythm respectively. The higher doses of

4

dronedarone 600 and 800 mg BD were found to lead to
higher discontinuation rates with no significant
incremental effects on maintenance of sinus rhythm,
suggesting a bell-shaped dose-effect curve of
dronedarone on rhythm-control. DAFNE has established
an optimal dose of 400 mg BD of dronedarone for
subsequent clinical studies.
The results of DAFNE drove the implementation
of two pivotal trials on dronedarone. They were
EURIDIS (European Trial in Atrial Fibrillation or Flutter
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Patients Receiving Dronedarone for the Maintenance
of Sinus Rhythm) and ADONIS (American-AustralianAfrican Trial With Dronedarone in Atrial Fibrillation/
Flutter Patients For the Maintenance of Sinus Rhythm).
They were multi-center, placebo-controlled, doubleblinded studies with similar designs performed in
different parts of the world.22 The presence of at least
one episode of AF within the last 3 months and the
presence of sinus rhythm that persisted at least 1 hour
preceding randomization were pre-requisites for
recruitment. Both studies had a 1-year follow-up period.
A total of 1,237 patients were randomized to receive
dronedarone 400 mg BD or placebo in a ratio of 2:1.
The time to first recurrence of AF or atrial flutter was
the primary endpoint.
Combining EURIDIS and ADONIS, dronedarone
400 mg BD was shown to significantly prolong the
median times to first AF recurrence compared to placebo
(116 days vs 53 days). AF recurrence rates at 1 year
was 64.1% in the dronedarone arm and 75.2% in the
placebo arm (HR 0.75, 95% CI 0.65-0.87, p<0.0001).
On the other hand, 37.7% and 46% of patients in the
dronedarone and placebo arms, respectively suffered
from symptomatic recurrences (p<0.001). Both studies
demonstrated significantly lower mean ventricular rates
in the dronedarone arms during AF recurrence compared
to placebo arms. There was no significant difference in
the percentage of patients reporting adverse events
between the 2 groups (67.4% in dronedarone group vs
62.8% in placebo group). Study discontinuation rates
due to adverse events were 9.5% with dronedarone and
6.1% with placebo. Gastrointestinal symptoms,
primarily diarrhea, were more commonly encountered
in the dronedarone group.
The results indicated that dronedarone was
effective increasing the time to first AF recurrence (116
days in the dronedarone group compared with 53 days
in the placebo group (HR=0.75, 95% CI, 0.65-0.87,
p<0.0001) and in reducing ventricular rate. The
proportion of patients who remained free of symptomatic
AF or AFL after 1 year was 62.3% (25% risk reduction
when compared with placebo, p<0.001) in the
dronedarone group. Post-hoc analysis also revealed a
27% reduction in all cause hospitalization and death

J HK Coll Cardiol, Vol 18

(22.8% vs 30.9%, p<0.01). Even though there was a
2.4% increase in serum creatinine in the dronedarone
group, discontinuation rates due to adverse events were
low (9.5% with dronedarone and 6.1% with placebo).

Dronedarone in Heart Failure
(ANDROMEDA)
Dronedarone has been studied in patients with
moderate to severe heart failure. ANDROMEDA
(Antiarrhythmic Trial With Dronedarone in Moderateto-Severe Congestive Heart Failure Evaluating
Morbidity Decrease) was a mortality trial in which
dronedarone was compared with placebo in patients with
moderate to severe heart failure, regardless of presence
of AF history.23 Patients hospitalized with symptomatic
heart failure who had suffered at least one episode of
dyspnoea on minimal exertion or at rest (NYHA Class
III-IV) or paroxysmal nocturnal dyspnoea within a
month before admission were randomized to receive
dronedarone 400 mg BD or placebo. Left ventricular
ejection fraction ≤35% was a pre-requisite for inclusion.
The trial was stopped prematurely 7 months after the
first patient had been randomized due to excess mortality
in the dronedarone arm. Twenty-five patients (8.1%) in
the dronedarone arm and 12 patients (3.8%) in the
placebo arm died (hazard ratio 2.13, 95% CI 1.07-4.25,
p=0.027) (Figure 2). The excess mortality in the
dronedarone arm was primarily due to worsening of
heart failure, with the mortality risk highest in those
with the most severely reduced left ventricular systolic
function. There are a few possible explanations for this
observation. Firstly, the small mortality difference of
13 patients between the two arms might have occurred
by chance due to early termination of the study.
Secondly, potent inhibition of peak sodium current and
resultant impairment of ventricular contractility by
dronedarone may cause worsening of heart failure.
Lastly, a retrospective analysis identified a higher death
rate in patients who were withdrawn from angiotensinconverting enzyme inhibitors and/or angiotensin
receptor blockers in response to a rise in creatinine level
with dronedarone. However, the contribution of this to
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the increased mortality in the dronedarone arm is
uncertain. Regardless of the exact mechanism,
ANDROMEDA study does define a subset of patients
not suitable to receive dronedarone.

dronedarone group vs 8.1% in the placebo group).
However, the frequency of gastrointestinal (26.2% vs
22%) and dermatologic (10.3% vs 7.6%) adverse effects
and the frequency of increased creatinine levels (4.7%
vs 1.3%) were significantly higher in the dronedarone

Clinical Cardiovascular Outcome Study
for Dronedarone (ATHENA)
The ATHENA (A Placebo-Controlled, DoubleBlind, Parallel Arm Trial to Assess the Efficacy of
Dronedarone 400 mg bid for the Prevention of
Cardiovascular Hospitalization or Death from any Cause
in Patients with Atrial Fibrillation/Atrial Flutter) trial
was a landmark study which evaluated the impact of
adding dronedarone to standard rate controlling agents
and anticoagulants in the management of AF.16 The
study was designed to compare the effect of dronedarone
400 mg BD with placebo in a randomization ratio of
1:1, on the prevention of cardiovascular hospitalization
or mortality. Patients with paroxysmal or persistent AF
or atrial flutter and at least one additional risk factor
for cardiovascular events, including age ≥75 years,
hypertension, diabetes mellitus, prior stroke or
transient ischaemic attack, left atrial enlargement of
≥5 cm or depressed left ventricular ejection fraction of
<40% were enrolled. The presence of advanced
congestive heart failure was one of the exclusion criteria.
The primary endpoint was first cardiovascular
hospitalization or mortality from any cause and the
secondary endpoints included mortality from any
cause, cardiovascular mortality and first
cardiovascular hospitalization.
With a mean follow-up duration of 21±5 months,
32% of patients in the dronedarone arm and 39% of
patients in the placebo arm reached the primary endpoint
(HR 0.76, 95% CI 0.69-0.84, p<0.001) (Figure 3).
Dronedarone reduced the first cardiovascular
hospitalizations by 26% (p<0.001), and cardiovascular
mortality and arrhythmic mortality by 29% (p=0.034)
and by 45% (p=0.01) respectively. However, all-cause
mortality was not significantly different between the
two groups.
The rate of drug discontinuation was not
significantly different between the groups (12.7% in the

6

Figure 2. Upper panel: Kaplan-Meier cumulative incidence
curves for all-cause mortality or hospitalization for worsening
of heart failure in the ANDROMEDA trial among patients
allocated to receive dronedarone or placebo. Lower panel:
Kaplan-Meier incidence curves for all-cause mortality.
(Reproduced from Kober L, Torp-Pederson C, McMurray JJ,
et al. Increased mortality after dronedarone therapy for severe
heart failure. N Engl J Med 2008;358:2678-87 with the
permission from Massachusetts Medical Society)23
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arm compared to the placebo arm. Regarding the
incidence of pulmonary and thyroid adverse effects, no
significant difference was observed between the two
groups.
A post-hoc analysis revealed that patients who
received dronedarone experienced a 34% reduction
in the risk of stroke (HR=0.66, 95% CI=0.46-0.96,
p=0.03) and a 30% reduction in hospitalization due
to acute coronary syndrome (HR=0.70, 95% CI=
0.51-0.79, p=0.03). 24 Interestingly, patients who
remained in AF after treatment also experienced

improved outcomes with dronedarone and that the
benefits of treatment were not limited to patients who
were converted to sinus rhythm.25

Dronedarone versus Amiodarone
(DIONYSOS)
Dronedarone was compared to amiodarone
directly with respect to safety and efficacy for sinus
rhythm maintenance in patients with AF in DIONYSOS

Figure 3. Kaplan-Meier cumulative incidences of the primary and secondary outcomes in the ATHENA trial. Treatment with
dronedarone significantly reduced the occurrence of (I) the composite primary outcome of first hospitalization due to
cardiovascular events or death from any cause (hazard ratio [HR] 0.76), (III) secondary outcomes of death from cardiovascular
causes (HR 0.71), and (IV) first hospitalization due to cardiovascular events (HR 0.74). (II) There was no difference in all-cause
mortality (HR 0.84). (Reproduced from Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular
events in atrial fibrillation. N Engl J Med 2009;360:668-78 with the permission from Massachusetts Medical Society)16
J HK Coll Cardiol, Vol 18
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(Dronedarone versus Amiodarone for the maintenance
of sinus rhythm in patients with atrial fibrillation).26
The study compared dronedarone 400 mg BD with
amiodarone 200 mg daily (with loading of 600 mg daily
for 4 weeks) during a mean follow-up of 7 months in
504 patients with documented AF of >72 hours for
whom cardioversion and anti-arrhythmic drugs were
indicated. The primary endpoint was recurrence of AF
or drug discontinuation as a result of drug intolerance
or lack of efficacy.
In DIONYSOS, fewer amiodarone-treated
patients reached the primary endpoint compared with
those treated with dronedarone (55.3% vs 73.9%,
p<0.001). Dronderaone was less effective in maintaining
sinus rhythm compared to amiodarone after
cardioversion (AF recurrence post-cardioversion in the
dronedarone and amiodarone arm was 36.5% and
24.3% respectively). More gastrointestinal adverse
events, namely diarrhea, vomiting and nausea and fewer
cardiac adverse events, namely bradycardia (2% vs
6.3%) and QTc prolongation (10.9% vs 20.5%) were
noted in the dronedarone arm.
A study comparing dronedarone with other antiarrhythmic drugs on major morbidity and mortality
outcomes in the treatment of AF, using a mixed
treatment comparison was recently reported. 27
Dronedarone was compared to other anti-arrhythmic
drugs, namely amiodarone, flecainide, propafenone and
sotalol in terms of all-cause mortality, stroke and serious
adverse events. For all-cause mortality, 8 randomized
controlled trials with 8,252 patients and 349 deaths were
included. There was no increase in mortality with use
of dronedarone compared to placebo. There was
significantly less mortality comparing dronedarone with
amiodarone (p=0.032) or sotalol (p=0.009). For stroke,
5 randomized controlled trials with 7,034 patients and
138 strokes were included for analysis. Dronedarone
was shown to decrease risk of stroke compared to
placebo (p=0.015). No significant reduction of stroke
was present with use of amiodarone or sotalol compared
to placebo. However, no significant difference can be
shown in the risk of stroke among different antiarrhythmic drugs. For serious adverse events, 18
randomized controlled trials with 8,351 patients and
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1,433 serious adverse events were included. Compared
to placebo, no significant difference was found for all
anti-arrhythmic drugs. And there was also no significant
difference in serious adverse events between different
anti-arrhythmic drugs.

Position of Dronedarone in the
Anti-arrhythmic Armamentarium
The safety and efficacy profile of dronedarone in
the treatment of AF has been well studied by different
clinical trials, namely ERATO, DAFNE, EURIDIS,
ADONIS, ANDROMEDA and ATHENA. It is a new
anti-arrhythmic drug with acceptable safety and modest
efficacy in rhythm-control for AF. It is also an effective
drug for rate-control. Dronedarone is less effective than
amiodarone in rhythm-control for AF, as shown by
DIONYSOS. However, it has a better safety profile with
absence of different types of organ toxicities associated
with amiodarone. With safety considered to be a priority
in the use of anti-arrhythmic drugs for AF, dronedarone
has been proposed to be the first-line agent in
maintenance of sinus rhythm in different subsets of
patients, except in patients with NYHA Class III or IV
heart failure.28 With the unavailability of dofetilide, an
adapted form of anti-arrhythmic treatment algorithm for
AF in Hong Kong is suggested in Figure 4. Dronedarone,
however, has not been incorporated into contemporary
practice guidelines by academic bodies or professional
organizations. The evidence for choosing dronedarone
over other first-line anti-arrhythmic drugs, at present, is
still obscure. However, based on the favourable
cardiovascular outcomes in ATHENA, dronedarone is
particularly preferred in the patient subset with
paroxysmal or persistent AF or atrial flutter and at least
one additional risk factor for cardiovascular events.

Conclusions
Dronedarone is a new generation of antiarrhythmic drug for the treatment of AF. It is the first
anti-arrhythmic agent shown to reduce the combined
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Figure 4. Suggested anti-arrhythmic treatment algorithm for the management of atrial fibrillation in Hong Kong.

outcome of cardiovascular hospitalization or mortality
in patients with AF. Dronedarone has been shown to
maintain sinus rhythm with modest efficacy and control
ventricular rate satisfactorily during episodes of AF.
When compared with amiodarone, dronedarone is less
effective in reducing AF recurrence, but possesses better
safety profile. Use of dronedarone, however, should be
limited to patients without severe heart failure (NYHA
class III or IV) as evidenced by ANDROMEDA.
The tolerability profile of dronedarone is good
with gastrointestinal symptoms like nausea, vomiting
and diarrhea as the most commonly encountered side
effects. There is no clinically significant interaction with
warfarin. Some patients may experience prolongation
of QTc interval but the occurrence of torsades de pointes
is rare. The drug may also cause a reversible increase
in serum creatinine level but the effect is not associated
with a reduction in renal function.

J HK Coll Cardiol, Vol 18

On the basis of the safety and efficacy portfolio
of dronedarone and the favourable cardiovascular
outcomes from ATHENA, the new anti-arrhythmic
drug has been approved by the United States Food and
Drug Administration for use in non-permanent AF
or atrial flutter to reduce the risk of cardiovascular
hospitalization.29 In clinical practice, taking safety as
the priority, dronedarone may be considered the firstline anti-arrhythmic drug for maintenance of sinus
rhythm in AF except in patients with moderate to severe
heart failure.
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Pacing Technology: Advances in Threshold Management
CHUNG-WAH SIU1 and CHU-PAK LAU2
From 1Research Center of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong and 2Cardiology
Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong
SIU AND LAU: Pacing Technology: Advances in Threshold Management. Over the last 5 decades, pacemaker
therapy has undergone remarkable technological advances with increasing sophistication of pacemaker features.
However, device longevity has remained one of the major issues in pacemaker design ever since the first
endocardial pacing lead implantation in 1958. In addition to various hardware design to enhance device longevity,
software-based solutions to minimize pacing energy and yet with good safety margin have also been developed.
Together with desire and need of fully automatic pacing system in increasingly busy pacemaker clinic, several
manufacturers have introduced different automatic threshold management algorithm. This article summarizes
the current state of art in pacing threshold management in the modern pacemakers. (J HK Coll Cardiol 2010;18:
11-16)
Capture management, pacemaker
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1958

Introduction
With the aging population, there have been an
increasing trend in cardiac pacemaker implantation
worldwide. In the United States, up to 2.25 million
electronic pacemakers were implanted in the period
from 1990 to 2002, and the annual implantation rate
increased almost 3-fold. Similar trend has also been
observed in Hong Kong with over 1,000 electronic
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pacemaker implanted in 2002. Despite pacemaker
therapy has undergone remarkable technologic advances
as reflected by the increase in number of circuitry
components from a mere two to three transistors in early
pacemakers to nearly 1 million components with
RAM size up to 124,000 bytes,1 the need and desire to
lengthen device longevity have remained one of the
major issues in pacemaker design ever since the first
endocardial pacing lead implantation in 1958. Hardware
improvements to improve device longevity including
high-energy density battery and high impedance, low
threshold leads have been developed. Likewise,
software-based solutions to pace the cardiac chamber
of interest with the lowest feasible energy with good
safety margin have also been developed. This article
summarizes the current state of art in pacing threshold
management in the modern pacemakers.

April 2010

11

PACING TECHNOLOGY

Capture Management
The primary function of a pacemaker is to pace
effectively at an efficient energy output, which in turn
depends on the pacing threshold that varies significantly
between individuals, and within an individual over time.
The intra-individual variation of pacing threshold
may occur due to spontaneous threshold rise after
implantation, gross or microdislodgment of pacemaker
lead, diurnal changes, and changes secondary to drugs
and/or myocardial ischemia. 2,3 From a clinical
standpoint, variation in threshold may lead to an
inadequate safety margin of stimulation, thus raising
potential safety issues. Thereby, the ability to track
threshold automatically will maximize patient safety,
minimize battery drain for pacing, and, importantly,
simplify programming. Furthermore, threshold
measurement remains time consuming, and if an
alternative and safe method is available, the burden
of programming can be reduced. Table 1 lists the
reasons necessitating automatic capture management.
Several manufacturers have introduced algorithms for
detecting ventricular, atrial, and left ventricular (in
cardiac resynchronization therapy (CRT)) thresholds.
The detection of an evoked response is based on either
evoked response or impedance. The threshold data are
used either on a beat-by-beat basis to ensure a paced
response or intermittently to adjust output parameters.

St. Jude/Pacesetter AutocaptureTM
S t . J u d e M e d i c a l fi r s t i n t r o d u c e d t h e
Autocapture TM pacing system in a single chamber

MicronyTM pacemaker in 1995. It is designed to verify
a response which represents capture or myocardial
depolarization, to each pacemaker stimulation, and
to automatically adjust the pacing output accordingly
in a beat-to-beat basis. Specifically, after a ventricular
pacing stimulus, the algorithm opens an evoked
response (ER) detection window for 46 ms after a
14 ms blanking period, and the detection of an ER is
used to diagnose capture (Figure 1). In the event that
an ER is not detected (loss of capture), a high energy
back-up pulse of 4.5 V is discharged at 100 ms after
the ventricular pacing stimulus, to avoid long pauses.
If two consecutive back-up pulses have been
delivered, the algorithm starts a stimulation threshold
search by increasing the output to effect two consecutive
captures. In single chamber devices (Microny and
Regency SR), a margin of 0.3 V is added. In addition,
to avoid pacing at high output due to diurnal fluctuation
in threshold, the device automatically performs a
threshold search once every 8 hours. A safety margin
of 0.3 V is added to the detected threshold. In dual
chamber devices, the A-V interval is shortened to
50 ms (Ap) or 25 ms (As) to ensure overdrive of intrinsic
ventricular rhythm. In the Affinity DR, automatic
decrements and increments of output during threshold
search are 0.25 and 0.125V, respectively. In addition,
beat-to-beat capture verification has recently been
extended to atrial stimulation in Zephyr pacemaker by
St. Jude Medical (ACPTM confirm), as the small atrial
electrical signal represents a major challenge in
discrimation between ER signal and pace-induced after
polarization.

Table 1. Potential benefits of capture management
Increase in battery drain (e.g., sensors, electrogram monitoring, and multisite pacing)
Increase in battery longevity
Two-third of patients will be alive at the time of battery replacement
Pacing for populations such as those with AF and after atrioventricular nodal ablation
Reduction in battery size
Physiologic/medical variation in threshold
Reduction in time for pacemaker programming
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The efficacy as well as the safety of the capture
management algorithm depends very much on accuracy
of detection of ER. Table 2 lists factors that affect
Autocapture detection of ER. One major challenge is
the difficulty to discriminate between the ER signal and
the pace-induced after potential; for instance, a large
electrode polarization artifact relative to size of ER can
affect ER detection. This can be reduced either with the
use of low polarization electrodes (made possible by
increasing the microscopic electrode-tissue interface
area),4 or with a biphasic waveform that comprises a
fast precharge followed by a negative postcharge to
minimize polarization effect.5 The effect of a modified
fast prepulse on AutocaptureTM algorithm was tested in
45 patients with leads from two manufacturers
(Medtronic 4024 Cap Sure, and Pacesetter 1450 K/T
and 1470 T leads).6 Whereas the ER was independent
of the type of pacing pulse, the polarization artifact was
significantly less during the modified pulse compared
with the conventional pacing pulse, leading to an
improved efficacy of the Autocapture algorithm (94%
versus 71% successful ER detection). An adequate ER
amplitude of greater than 2.5 mV is recommended
before activation of the autocapture algorithm, and this
was present in 93% of 60 patients in one study.7 Neither
the clinical data nor the conventional electrical
parameters were effective in predicting the size of the

ER signal. Body posture and exercise had relatively little
effect on the ER. 8 Recently, a new ER algorithm
measuring the depolarization integral (area) instead of
ER signal amplitudes (voltage) to determine ER has
enhanced the accuracy of capture verification; in fact,
the algorithm allows ER determination even with old
high polarization bipolar leads (Figure 2). Because of
the enhanced sensitivity, discrimination of small atrial
ER from pace-induced after potential has become
possible.
The one-year stability of the algorithm has been
tested in a multicenter study involving 113 patients

Table 2. Factors affecting capture detection
Electrode polarization
Fusion beats (false negative)
Ventricular capture, intrinsic beat
Pseudofusion beats (false positive)
Pacing spike (and failure of capture), intrinsic beat
Algorithm related: Unipolar pacing, bipolar sensing
Adequate ER
Other applications: atrial, epicardial, and left ventricle

Figure 1. Evoked response detection. After a ventricular pacing stimulus, the algorithm opens an evoked
response (ER) detection window for 46 ms after a 14 ms blanking period, and the detection of an ER
(voltage) is used to diagnose capture.
J HK Coll Cardiol, Vol 18
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Figure 2. Evoked response detection with depolarization integral (area) to determine ER.

implanted with Pacesetter Microny SR+. 9 Evoked
response was satisfactory for Autocapture in 102 of 113
patients, and the evoked response was stable over time.
Furthermore, both the acute and chronic pacing
thresholds measured at the clinic using VARIO
significantly correlated with that derived from
Autocapture, despite that the Autocapture threshold was
higher (0.11±0.22 V) owing to the way in which
threshold was derived. During Holter recordings, there
was no failure of ventricular capture, and back-up pulses
were used in 1.1% of all paced beats. Most were due to
fusion or pseudofusion beats (87%), undersensing of
either R wave or ER (4.6%), and truly due to loss of
capture in only 7%. Although these did not affect pacing
performance, the need for back-up pulses may negate
the energy saving by the Autocapture itself.
Consistently, similar positive results from the
Autocapture algorithm in medium term for safety and
efficacy have also been published. 10,11 Compared
with the factory-set pacemaker setting of 5 V,
AutocaptureTM algorithm reduced the energy drain in
the Microny SR+ (with 0.35 Ah), which translated into
an increased device longevity by 53%. For the Regency
SR+ with a larger battery (0.79 Ah), the increase in
device longevity was more remarkable (245%).
However, when the conventional output was reduced to
2.5 V, the benefit of Autocapture on battery life was
much less impressive.12,13

14

Boston Scientific Automatic Capture
Likewise, the automatic capture algorithm from
Boston Scientific provides also a beat-to-beat
verification of myocardial capture based on the
ventricular ER. The ventricular voltage output was
automatically adjusted to 0.5 V above the measured
threshold. Upon the occurrence of loss of capture, a
backup pacing pulse 1.5 V higher than the measured
threshold is delivered 100 ms after the primary stimulus.
When loss of capture is confirmed for two cycles out of
four beats, an automatic threshold test will check for
the new threshold.

Biotronik Capture Control
The Logos pacemakers from Biotronik measure
the ER signals from several successful capture beats, in
order to generate a reference curve, against which failure
of capture is compared.14,15 There are no back-up pacing
pulses, but persistent loss of capture results in increase
of pulse output in 2 V steps. After a programmable
period of time, the output is reduced to the programmed
value. This algorithm ensures patient safety through
beat-by-beat capture verification.

Medtronic Ventricular Capture Management
The Kappa 700 pacemakers from Medtronic
incorporate a threshold assessment based on ER: the
Pacing Threshold Search (ambulatory) and Capture
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Management Threshold Test (bedside). During the
procedure, the threshold at the Rheobase is
determined at 1 ms by amplitude decrement until loss
of capture followed by amplitude increment until
capture confirmed. The Chronaxie is then determined
by doubling the programmed amplitude, and
decreasing the pulse width (followed by increasing
amplitude to capture). A recommended pacing setting
is then determined. The physician can use the
ambulatory threshold data to automatically adjust the
threshold (adaptive), or to use for monitoring only,
or the algorithm can be turned off. A minimal adapted
output needs to be programmed. The ventricular
capture management can be activated once every 15
minutes for 42 days, and is not a beat-by-beat
threshold tracking algorithm. In a predictive analysis,
the device longevity of Medtronic Kappa 700 serues
pacemakers featuring three automatic algorithm
including Capture management, Sinus Preference,
and Search AV was tested in 22 patients.16 The overall
longevity with all three features programmed was
estimated to be 106.3±8.4 months with 8.1±5.8
months more compared with that without Capture
management and Search AV.

Summary
The increased sophistication in pacemaker
technology has led to pacemaker features that average
pacemaker implanters may not have the time either to
understand or to program appropriately, as well as
prolonged pacemaker interrogation time during regular
follow-up.17 The automaticity of the optimization of
many pacing parameters has significantly faciliated
daily clinical management. In fact, programming of
threshold can be simplified as the algorithm-determined
threshold was significantly correlated with conventional
threshold assessment. The main benefit of automatic
pacing threshold algorithm is to maintain effective
capture during threshold changes, to prolong device
longevity and to ensure patient safety. These algorithms
have be demonstrated to be safe and useful for
prolonging device longevity.9,11,18
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Scientific Programme
Friday, May 14, 2010
0800

Registration

0900-1030

Free Paper Session
Coronary Artery Disease I
Cardiac Arrhythmias, Electrophysiological Studies and Cardiac Rehabilitation

1030-1100

Coffee Break
Visit Exhibits

1100-1230

Free Paper Session
Percutaneous Coronary Intervention and Coronary Artery Disease II
Cardiac Imaging and Coronary Risk Factors

1230-1400

Light Lunch

1400-1515

Free Paper Session
Cardiac Surgery
Miscellaneous

1515-1600

Plenary Lecture
Time Delay to Treatment for Acute ST-segment Elevation Myocardial Infarction in Beijing
Dayi Hu

1600-1630

Coffee Break
Visit Exhibits

1630-1730

Plenary Lectures
Long Term Clinical Outcomes of Using SKB Technique to Treat Special LAD Ostial Lesion An Innovative Approach on LAD Ostial Stenosis
Jilin Chen
The Journey of an Ideal Stent
Harry Suryapranata

1730-1830

Best Paper Oral Presentation

1845-1900

Opening Ceremony

1900-2000

Hong Kong Heart Foundation Lecture
Transradial Intervention for Left-main Bifurcation Lesion
Yuejin Yang

2000-2130

Welcome Dinner
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0745

Registration

0815-1200

Joined Symposium - Cross-straits Medicine Exchange Association of Ministry of Health /
Hong Kong College of Cardiology
Guidelines and Practice: Clinical Case Based Conference (GAP-CCBC)
(Presentation in English or Putonghua)
Wellen's Syndrome
Lianfang Chang
Retrograde CTO Intervention
Yawei Xu
Emotional Problem - Fever and Dyspnea
Shaoliang Chen
Ventricular Fibrillation and No-reflow in CTO PCI
Haojian Dong
The Practice of Compromise in CTO PCI
Jianan Wang
Coronary Perforation During PCI
Yan Wang
Fever and Short of Breath
Ligang Fang
Iatrogenic Aortocoronary Dissection During CTO PCI
Weimin Li
Acute Coronary Syndrome with Fever
Jiangli Han
Left Main Dissection
I-chang Hsieh
Recurrent Chest Pain After CABG
Chiu-lai Fu

0930-1030

Allied Cardiovascular Health Professionals Symposium
Learn the Clinically Important ECGs in 2 Hours
Wide Complex Tachycardia
Yat-sun Chan
Narrow Complex Tachycardia
Andy Wai-kwong Chan

1100-1200

Allied Cardiovascular Health Professionals Symposium
Learn the Clinically Important ECGs in 2 Hours
Bradycardia and Normal Variant
Kwok-keung Chan
Cardiac Emergency
Chi-wo Chan
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1200-1330

Lunch

1330-1500

Eli Lilly Symposium
Optimizing Antiplatelet Therapy in ACS-PCI - Challenges and Solutions
Murtaza Qasuri
Improving Clinical Outcomes in ACS-PCI with Optimal Antiplatelet Therapy Evidence from TRITON TIMI 38
Derek Peng-beng Chew

1500-1600

Sixth Congregation of HKCC

1600-1730

Abbott Vascular Symposium
Guide Wire Selection in Chronic Total Occlusions
Craig A. Thompson
Vascular Restoration Therapy: The Abbott Vascular's Bioresorbable Vascular Scaffold Program
Douglas V. Follett
Transferability of Data Between Different Drug-eluting Stents
Bernard Bun-lap Wong

1730-1900

Plenary Lectures
Biodegradable Polymer DES in Complex Lesions
Satoru Sumitsuji
Statin Therapy: Optimising the Benefits
Brian Tomlinson
Atherosclerosis in Youth
Dong Zhao

1915-2030

Evening Symposium on Percutaneous Valvular Intervention
The New Era in Treating Aortic Stenosis - TAVI
David Muller
MitraClip - An Innovative Mechanical Solution to Mistral Regurgitation
Cheung-wah Cheng
Steven Siu-lung Li

2030-2200

Dinner

* Coffee will be served from 1000-1100 and 1700-1800 at 4/F of Sung Terrace.
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Sunday, May 16, 2010
0800

Registration

0830-1030

Plenary Lectures
Intervention in STEMI Patients with Left-main Occlusion
Lefeng Wang
Clinical Evidence that Early CRT Intervention Slows Heart Failure:
MADIT-CRT and 8 Years Result of MADIT II
Yat-sun Chan
ER Niacin / Laropiprant: A Novel Approach to Comprehensive Lipid Management
Albert Wai-suen Leung
Resolving Unmet Needs with Revolutionary Technologies
i) Resolute All Comers Trial
ii) Breakthrough Technology in Treating Cardiovascular Disease
David Muller

1030-1100

Coffee Break
Visit Exhibits

1100-1300

PCI Cases Discussion
Prize Presentation

1300-1430

Lunch

1430-1630

Joined Symposium - Asian Pacific Society of Cardiology / Hong Kong College of Cardiology
Management of Heart Failure in 2010
Role of Neurohormones in Guidance of Heart Failure Therapy
A. Mark Richards
Application of Biventricular Pacing System: Paradigm Shift from Heart Failure to
Non-systolic Heart Failure Patients
Cheuk-man Yu
Advances in Echocardiographic Imaging for Heart Failure with Normal Ejection
Gabriel Wai-kwok Yip
Non-pharmacological Treatment of Heart Failure
Wing-kuk Au

1630-1700

Coffee Break
Visit Exhibits

1700-1830

Plenary Lectures on Cardiac Arrhythmia
New Era in CRT: A True Haemodynamic Sensor for Auto-synchronization
Gerry Kaye
Cardiac Contractility Modulation (CCM) - From Basic Concepts to Clinical Practice
Yat-sun Chan
Atrial Fibrillation Ablation: Is Now Prime Time for Routine Clinical Practice?
Jeffrey Wing-hong Fung

1830-1930

Plenary Lectures on Cardiac CT & MRI
The Evolving Role of Cardiac CT in the Management of Coronary Artery Disease
Chi-ming Wong
Cardiac MRI in Acute Myocardial Infarction
Shang-jen Shu

1930-2100

Farewell Dinner
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Paediatric Cardiology Programme
Friday, May 14, 2010
1400-1530

Paediatric Cardiology Symposium I
Echo Determinants of One vs Two Ventricular Repair
Gerald Ross Marx
Early and Long-term Results for Correction of Total Anomalous Pulmonary Venous Drainage
Bing Jia
Slide Tracheoplasty
Lik-cheung Cheng

1600-1630

Coffee Break
Visit Exhibits

1630-1730

Free Paper Session
Paediatric Cardiology I

Saturday, May 15, 2010
0900-1030

Paediatric Cardiology Symposium II
Recent Clinical Applications of 3D Echo in CHD
Gerald Ross Marx
Retrospective Study on Transcatheter Closure and VSD Surgery Repair of Congenital Ventricular Septal
Defect in Children Focusing on Efficacy and in Mid-term and Long-term Follow-up Result
Zhiwei Zhang
Pulmonary Artery Hypertension Associated with Congenital Heart Disease
Lin Wu

1030-1100

Coffee Break
Visit Exhibits

1100-1200

Free Paper Session
Paediatric Cardiology II
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6.

5.

Local experience: Tenecteplase (TNK) as Thrombolytics for STEMI
Patients
NH Luk, WS Kwan, SF Chui, YH Cheng, LK Chan, KC Chan, HS Ma, CY
Wong, CW Chan, CL Fu, KY Lee, KT Chan, KC Ho, CS Chiang
Division of Cardiology, Department of Medicine, Queen Elizabeth Hospital,
Hong Kong SAR, China
Objective: The aim of this study was to evaluate the short term outcome and
complication of Tenecteplase (TNK) as thrombolytics for patients with ST
Eleation Myocardial Infarction (STEMI).
Methods: Hospital records of all STEMI patient treated with TNK since the
introduction of TNK in Queen Elizabeth Hospital (Oct 2009) were reviewed.
Demographic data, co-morbidities, outcome and complication were analyzed.
Result: Total number of 26 patents were given TNK for STEMI during the
study period. There was 23 male (88.4%) and 3 female (11.6%). Their mean
age was 61.1 +/- 11.1 years. The mean onset of pain to needle time was 5hrs
12mins. 13 of patients had anterior MI (50%) and 13 of them had inferior MI
(50%). 19 patients (73%) were showed to have successful thrombolysis.
Coronary angiogram had been performed following thrombolytics in 24 of
them (92%). None of them showed TIMI 0 flow. Four patients did not receive
coronary angioplasty: 3 of them showed minor disease only and 1 of them
showed triple vessels disease which later referred to cardiothoracic surgery.
None of them had complication of intracranial bleeding. One patient had
complication of upper gastrointestinal bleeding. None of them died of bleeding
complication. 3 patients (11.5%) died of other causes.
Conclusion: The short term outcome in local population of TNK is promising.
Further prospective studies are yet needed.

8.

7.
BMP9 Promotes Cardiac Progenitor Cells Ameliorate the Heart Function
in the Rat Model of Myocardial Infarction
L Zhao, Y Chen, B Shen, LG Zhou, H Wei and ZL Zhang
Department of Heart Center, Children's Hospital of Chongqing Medical University,
Chongqing, PR China
Purpose: To observe whether cardiac progenitor cells (CPCs) which induced by
bone morphogenetic proteins9 (BMP9) can improve the heart function of the rat
with myocardial infarction.
Methods: CPCs were infected by AdBMP9 which express green fluorescent protein.
After twenty-four hours, the expression of BMP9 mRNA of infected CPCs were
examined by semi-quantitative RT-PCR. Then, infected CPCs by AdBMP9 were
injected into the infracted heart. The hearts were collected, after postoperative four
weeks. The change of CPCs morphology was observed by HE staining and
immunofluorescent analysis to investigate the expression of cardiac-specific
structural proteins alpha myosin heavy chain (a-MHC) and a-Actin of the implanted
CPCs. The cardiac infarct size was detected by Masson staining. Heart function
was examined by echocardiography, in preoperative and postoperative four weeks.
Result: After twenty-four hours, the expression of BMP9 mRNA of CPCs infected
by AdBMP9 improved significantly. The result of HE staining and
immunofluorescent showed that the grated-CPCs could fuse with the normal
cardiomyocytes and expressed the cardiac-specific proteins a-MHC and a-Actin,
at four weeks after transplantation. But the expression of cardiac-specific structural
proteins is lower than the abnormal cardiac tissue. At postoperative four weeks,
the implanted CPCs can reduce the size of infracted obviously (P<0.02) and which
can be promoted by BMP9 (P<0.001). The result of heart function is similar with
the Masson staining.
Conclusion: CPCs induced by BMP9 can improve the heart function of the rat
with myocardial infarction.
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13.

14.

15.

16.
Effects of Aerobic Exercise Training on Exercise Capacity, Cardiac Function
and Quality of Life in Chronic Heart Failure Patients with Cardiac
Resynchronization Therapy - A Pilot Study
BKLYunk,1 AYM Jones,3 K Fan,2 WH Chow2
Physiotherapy Department and 2Cardiac Medical Unit, Grantham Hospital & 3Department
of Rehabilitation Sciences, Hong Kong Polytechnic University

1

Purpose: The objective of this study was to investigate the exercise capacity, cardiac function
and quality of life in patients with chronic heart failure prior to cardiac resynchronization
therapy (CRT), after one month of implantation and after an eight weeks aerobic exercise
training programme.
Methods: From April 2008 to November 2009, 7 chronic heart failure patients with
ambulatory NYHA functional class IV (5 men and 2 female) underwent CRT implantation
and were randomized to either the aerobic exercise group or control group. The aerobic
exercise group performed 8-week aerobic exercise training program under close supervision
and the control group remained physically inactive.
Results: Four subjects (two of them being heart transplant candidates) were allocated to
the aerobic exercise group and three patients were allocated to the control group. Two
subjects in aerobic exercise group were withdrawn due to heart transplantation and repeated
gouty attacks on lower limbs respectively. After one month of CRT implantation, the peak
oxygen consumption (VO2max), 6-minutes walk test distance and quality of life score for
all subjects were similar to baseline but left ventricular ejection fraction has improved
from 29.5±6.6 to 36.0±7.2 %. After eight weeks of aerobic exercise training, the two
remaining subjects in the aerobic exercise group showed an increase in VO2max(Exercise:
26.5% ,control: 11.8%), peak heart rate (Exercise: 15.1% , control: 3.6%), decrease in left
ventricular end diastolic diameter (Exercise: -2%, control: 0.9%), left ventricular end systolic
diameter (Exercise: -7% control: 0%), mitral regurgitation score (Exercise: -100%, control:
28%). One female subject in aerobic exercise group was successfully removed in heart
transplantation list during exercise phase.
Conclusion: Aerobic exercise training is safe and feasible for chronic heart failure patients
with CRT. On-going collection of data is required to show the improvement on physical,
quality of life and other parameters of cardiac function such as mitral regurgitation, left
ventricular end diastolic end systolic diameter.
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22.

23.
GenousTM Experience - A Local and Global Perspective on ACS and Special
Indication Patients
SWL Lee
Department of Medicine, Queen Mary Hospital, Hong Kong

The GenousTM Endothelial Progenitor Cell (EPC) capturing stent has been
clinically demonstrated to be a safe stent that helps reduce thrombosis and
restenosis despite only a 4-week duration of dual anti-platalet therapy (DAPT)
as according to on-label use. In consistency with recent publications and
clinical releases on STEMI patients treated with the EPC stents, a total of 174
patients (including 29.9% STEMI patients and 26.4% NSTE-ACS patients)
at Queen Mary Hospital (QMH) implanted with the stent also showed
comparable findings. In addition, a small number of patients with special
indications (e.g. drug intolerance, inability to withstand prolonged DAPT,
bleeding issues and peri-operative etc.) also benefited from the EPC stent
with favorable results.
Enrollment and Method: ACS and special indication patients with postprocedural DAPT of 4 weeks as according to on-label use.
Results/Outcomes: MACE at 30 days was 5.7% (10); Cumulative MACE at
3 months was 6.8% (12); Cumulative MACE at 1 year was 11.5% (20);
Cardiovascular mortality at 1 year was 5.2% (10); Clinically-driven TLR at
1 year was 5.7% (10); Subacute Stent Thrombosis: 0.6% (1); Late Stent
Thrombosis: 0.6% (1).
Clinical follow-up data (overall and ACS subgroup) from QMH appears
consistent with data from the worldwide 5,000-patient e-Healing Registry
(primary outcome of MACE: 7.7%; SAT: 0.2%; LST: 0.3%). To further address
the issue of restenosis, a multi-center randomized in-human trial called
REMEDEE has been initiated to demonstrate the safety and efficacy of a
combo stent that both promotes accelerated healing whilst reducing cell
proliferation.
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Department of Cardiology, St. John's Medical College Hospital, Bangalore, India

J HK Coll Cardiol, Vol 18

April 2010

37

HK COLLEGE OF CARDIOLOGY, EIGHTEENTH ANNUAL SCIENTIFIC CONGRESS
ABSTRACTS
Abstracts for Free Paper Session:

47.

48.

49.

50.

38

April 2010

J HK Coll Cardiol, Vol 18

HK COLLEGE OF CARDIOLOGY, EIGHTEENTH ANNUAL SCIENTIFIC CONGRESS
ABSTRACTS
Abstracts for Free Paper Session:
52.

51.

Effects of Hydrogen Sulfide on the Expressions of bax and bcl-2 in
Hippocampi of Rats after Cardiopulmonary Resuscitation.
Ji-yan Lin, Hong-yan Wei, Hui Li, Xin Li, Rong Liu, Chun-lin Hu, Guo-qing Huang,
Gang Dai, Xiao-xing Liao on behalf of Department of Emergency, the First Affiliated
Hospital of Sun Yat-Sen University, Guangzhou, China
Purpose: To examine the expression of bax and bcl-2 in the hippocampi of rats and
investigate the effects of hydrogen sulfide (H 2S) on neurons apoptosis after
cardiopulmonary resuscitation (CPR).
Methods: There were 160 male SD rats, the 108 rats were initially selected and
randomly divided into 3 groups equally. Model of cardiac arrest were induced by
transcutaneous electrical epicardium stimulation and standard CPR were offered in
all the subjects. After ROSC, the First group were given sodium bisulfide, the second
group were given hydroxylamine, and the third group were only given routine CPR.
Above-mentioned the three groups were further divided three sub-groups based on
the observed end point (1, 3 or 7 days), then each sub-group were divided into two
groups equally and given them relevant examination such as Immunohistochemistry
or RT-PCR of bax and bcl-2.
Results: (1) Numbers of substitutes and mortality rate after ROSC were no significant
difference among the three groups (P>0.05). (2) There were significant differences
in the serum levels of H2S among the three groups on 1, 3 and 7 days after ROSC
(P=0.000). (3) On 1, 3 and 7 days after ROSC, the sum of integrated optical density
(IOD) of bax and bcl-2 in the hippocampi CA1area among the three groups had
statistic significance (P<0.05). And in every group, there were significant differences
in the sum of IOD of bax and bcl-2 in the hippocampi CA1area among the three
observed end points (P<0.01). (4) On 1, 3, and 7 days after ROSC, the expressions
of bax mRNA and bcl-2 mRNA in the hippocampi among the three groups had
statistic significance (P<0.01). And in every group, there were significant differences
in the expressions of bax and bcl-2 in the hippocampi among the three observed end
points (P=0.000).
Conclusion: H2S may be take part in neurons apoptosis by imbalance of bcl-2/bax.

53.

54.

Change of Hydrogen Sulfide Content in Serum of Rats After Cardiopulmonary
Resuscitation
Xiao-xing Liao, Ji-yan Lin, Hong-yan Wei, Hui Li, Xin Li, Rong Liu, Chun-lin Hu,
Guo-qing Huang, Gang Dai on behalf of Department of Emergency, the First Affiliated
Hospital of Sun Yat-Sen University, Guangzhou, China
Purpose: To investigate variation of hydrogen sulfide (H2S) in serum of rats after
cardiopulmonary resuscitation (CPR) and explore its pathophysiological role in CPR.
Methods: The 30 male SD rats were randomly divided into control groups (n=6)
and experimental group (n=24), then models of cardiac arrest (CA) were established
in rats of experimental group by transcutaneous electrical epicardium stimulation.
Blood samples were collected before CA, at 2, 4, 6, 8, 10 and 12h after restoration
of spontaneous circulation (ROSC) for testing the serum levels of H2S, at the same
time rectal temperature (Tr), mean arterial pressure (MAP), heart rate (HR) and
respiration rate (R) were record. Next to analyze the dynamic variation of H2S content
in serum of the rats after CPR and its correlation of the above-mentioned signs of
life.
Results: (1) In experimental group, all of the 24 rats were successfully induced CA
and resuscitation; at end points (12h after ROSC) there were 14 rats were alive and
their vital signs were stable. There was no death in the control group. (2) The variation
trend of H2S content in serum was different between experimental group and the
control (F=12.226, P=0.003). In experimental group, H2S content in serum increased
dramatically after CPR and reached peak at 6h after ROSC, then return to the similar
level of the control group. (3) H2S content in serum was negatively correlated with
Tr (partial r=-0.556, P=0.000) and MAP (partial r=-0.240, P=0.002). But it wasn't
correlated with HR and R (P>0.05).
Conclusion: Change of H2S content in serum of rats after CPR may be a manifestation
of compensatory responses after ROSC and participate in physiological processes
such as body temperature and blood pressure regulation. But as for its precisely
mechanisms, it still needs to be studied further.
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YM Xie
Department of Pediatric Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital,
Guangzhou, PR China
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59.

60.

61.
Research of N-terminal Pro-brain Nitric Peptide for Congenital
Heart Disease with Pulmonary Hypertension
Li Yun-Quan, Wang Hui-Shen, Li Shu-Juan, et al.
Department of Pediatric Cardiology, The First Affiliated Hospital of Sun Yatsen University, Guangzhou 510080, China
Objective: To investigate whether serum N-terminal Pro-Brain Nitric Peptide
(NTpro-BNP) levels could reflect the severity of pulmonary arterial
hypertension in children with congenital heart disease (CHD).
Methods: We performed a retrospective study to determine if serum NTproBNP levels varies by pulmonary artery systolic pressure (PASP) by
catheterization. The population included a group of 27 pediatric patients from
2006 to 2009. All patients were diagnosed with CHD of left to right and had
serum NTpro-BNP and catheterization. Exclusion criteria were impaired renal
function (serum creatinine level >115 µmol/L), decreased left heart function
(LVEF <50%), and stenosis of outlet of right ventricle. Serum NT-proBNP
were measured using the electrochemiluminescence immunoassay. Statistical
analysis of the linear correlation of NT-pro BNP and PASP were carried out.
Results: The NT-proBNP concentration can reflect the degree of PASP
(r=0.58, AP=0.001). Using serum NT-proBNP concentration ≥134pg/ml as
the cut point for diagnosing slight and medium PAH, the sensitivity was 90%,
the specificity 86%, and ≥499.0pg/ml as the cut point for diagnosing serious
PAH, the sensitivity and specificity was 64% and 82% respectively.
Conclusion: We concluded that serum NT-proBNP levels parallel changes
with PASP. Serum NT-proBNP could be a useful marker to monitor disease
severity in pediatric pulmonary hypertension.
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63.
Cited2 mutation associated with congenital heart disease
XF Yang, XY Wu, J Tian
Department of Heart Center, Children's Hospital of Chongquing Medical
University, Chongquing, China
Purpose: To explore gene mutation of Cited2 coding strand in Chinese patients
with congenital heart disease (CHD).
Methods: DNA was abstracted from the blood samples of 120 nonhomologous
and various CHD patients and 100 healthy children. The coding regions of
Cited2 was amplified by PCR and compared to the Gene Bank after sequencing
to identify the mutations. The families of the samples who have Cited2
mutations were investigated as well. ClustalW software was amplified for
conservative analysis of the altered amino acids.
Result: 3 new mutations of Cited2 coding strand were found in 4 CHD patients.
2 point mutations were first identified respectively in two patients, one patient
with mirror image dextrocardia and tetralogy of Fallot (c.550>A), another
with aortic stenosis (c.574 A>G). Apart from this, the same deletion (c.573578del6) was first detected in other two patients, one patient with ventricular
septal defect and atrial septal defect, anothor with aortic stenosis and pulmonary
stenosis. All the mutations resulted the protein changes (p.Gly184Ser;
p. Ser192Gly; p. Ser192fs). All the changes were not detected in the control
group.
Conclusion: This study show for the first time that there are 3 brand-new
gene mutations of Cited2 in Chinese CHD patients with a broad phenotype
spectrum. Serine-glycine rich junction (SGJ) is considered as the mutation
hot spot. Cited2 mutations may be one of the causative impact in development
of CHD in human.

64.
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67.
Outcome of Surgical Repair of Coronary Artery Fistulas in Children
Y Pan and B Jia
Heart Center, Children's Hospital, Fudan University, Shanghai, China
Purpose: Coronary artery fistulas (CAF) are rare congential malformations
that can be seen in 0.06% of children undergoing echocardiography and 0.
13%-0.22% of adults undergoing coronary angiography. There are no good
large, complete, long-term comparative studies of a significant number of
patients. Our aim of this article is to attempt to review the limited information
and the outcome of surgical repair of the rare malformations in our center.
Methods: we review the clinical characteristics and surgical outcome of thirteen
patients with CAF in our center from 1993-2009. The median age was 26
months (2 months, 150 months). Six patients were male and seven were female.
All patients were first diagnosed with CAF by echocardiography, eight of
them were undergoing angiography. Only two patients were asymptomatic.
Surgical repair include ligation, stitch and patch repair, ten patients had
cardiopolmunary bypass. Four patient with aneurysm underwent coronary artery
plasty at the same time. No anticoagulant drugs were used.
Result: The longest follow up was 16 years, median was 5 years. NO surgical
death and late death, TEE showed no residual fistulas right after operation.
Two patients were found fitulas in different site by echocardiography in CCU,
and both had successful second operation. No recurrent fitulas, no progressive
dilation of coronary arteries, no AMI in follow up.
Conclusion: we suggested that all patients with CAF should be treated. Surgical
repair is a safe and effective treatment for children. According to our current
follow up, patients can live an event-free life in a long time after surgery.

68.
Minimally Invasive Transthoracic Device Closure of Ventricular Septal
Defect without Cardiopulmonary Bypass: A New Hybrid Technique and
Multi-center Experience
QS Xing,1 SL Pan,1 Q Wu,1 ZW Zhang,2 JH Li,2 Q An,3 XZ Wang4
Children's Heart Center, Qingdao Children's Hospital, 2Department of Cardiac
Surgery, West China Hospital, Sichuan University, 3Shanghai Chest Hospital and
4
Zejiang University Children's Hospital, PR China
1

Objective: To introduce a new minimally invasive technique of perventricular
closure of ventricular septal defect (VSD) without cardiopulmonary bypass under
transesophageal echocardiography (TEE) guidance and summary the clinical
experiences and mid-term follow-up results.
Methods: A total of 408 cases in 4 centers, 5 months to 15 years (3.1 1.7 years),
underwent perventricular device closure, with a body weight of 4.5 to 26 kg (13.6
55kg). A small inferior sternal incision was made. A single purse-string suture
was placed on the right ventricular free wall and a guidewire was inserted through
the right ventricle cavity across VSD to the left ventricle under TEE guidance. A
delivery sheath was introduced over the guidewire to the left ventricle cavity. And
then a proper sized device was delivered and released under TEE monitoring on the
beating heart.
Results: 393 cases of this group were successfully closed (96.3%) and the other 15
cases (3.7%) converted to traditional open head repair. 213 (54.2%) were implanted
a symmetrical device and 180 (45.8%) were closed with asymmetrical ones. 387
cases (96.5%) received no transfusion or blood products. New tiny or mild tricuspid
regurgitation (TR) was found in 13 cases (3.3%), but no worsening regurgitation in
those with existed TR. Incomplete right bundle block from ECG happened in 11
cases (2.8%). Most discharged 3 to 5 days after operation. All cases were followupped for 3 months to 2 years, without residue shunt, new or aggravating aortic
regurgitation, obstruction of left or right outflow tract and device dislocation.
Conclusion: Minimally invasive perventricular device closure of VSD off CPB is
a simple, effective and safe intervention under guidance of TEE. It is agreeable to
considerable VSD clients and clinically valuable to be promoted. Long-term followup is necessary.
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